Every Form 4 that Cassava Sciences, Inc. (SAVA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow SAVA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SAVA filings page.
Cassava Sciences Inc. (SAVA) reported an insider stock transaction by a director. On 11/24/2025, the director purchased 8,600 shares of Cassava Sciences common stock in an open-market transaction coded as a purchase (code "P"). The shares were acquired at a price of $2.90 per share, and following this transaction, the director beneficially owned 8,600 shares with direct ownership.
Cassava Sciences (SAVA) President and CEO, who is also a director, reported an open-market purchase of common stock. On 11/20/2025, a trust for the reporting person bought 150,000 Cassava shares at a weighted average price of $2.76 per share, with individual trades executed between $2.74 and $2.80.
After this transaction, the trust beneficially owns 938,060 shares of Cassava common stock, reported as indirect ownership. The filing notes that full detail on the number of shares purchased at each price within the range is available upon request.
Cassava Sciences (SAVA) reported an insider stock purchase by its President and CEO, who is also a director. On 11/19/2025, a trust associated with the reporting person bought 73,385 shares of Cassava Sciences common stock in open market transactions at a weighted average price of about $2.75 per share, with individual trade prices ranging from $2.73 to $2.75 per share. After this transaction, the trust beneficially owns 788,060 shares of Cassava Sciences common stock.
Cassava Sciences (SAVA) reported a director stock option grant. On 10/21/2025, the director received a stock option for 53,000 shares with an exercise price of $3.98 per share and an expiration date of 10/21/2035. The option vests over three years at 1/36th each month. Following the grant, 53,000 derivative securities were beneficially owned, held directly. The grant price for the option was reported as $0.
Robert Christopher Cook, listed as Chief Operating & Legal Officer and a director of Cassava Sciences, Inc. (SAVA), reported an insider purchase on 09/30/2025. The Form 4 shows an acquisition of 13,725 shares of common stock at a price of $2.91 per share, and the filing reports 13,725 shares beneficially owned following the transaction. The report was signed under power of attorney on 10/02/2025.
Cassava Sciences insider purchase by CEO and director. Barry Richard, serving as President & CEO and a director, reported open-market purchases of 7,172 shares of Cassava Sciences Inc. (SAVA) on 09/22/2025 at a weighted average price of $2.28 per share (individual trades ranged $2.27–$2.29). After the transactions the reporting person beneficially owns 714,675 shares indirectly through a trust. The Form 4 was signed by power of attorney on 09/23/2025.
Cassava Sciences (SAVA) Director and President & CEO Barry Richard reported multiple open-market purchases of the company's common stock on September 18-19, 2025, acquiring a total of 237,941 shares at prices between $2.13 and $2.29. Following these transactions he beneficially owned 707,503 shares, held indirectly through a trust. The Form 4 was signed by an authorized POA on September 22, 2025.